Compulsory Licensing of Patents: The Bayer/Natco Case

(2012) European Intellectual Property Review (Issue 10), pp. 719-728

10 Pages Posted: 6 Oct 2012

See all articles by Enrico Bonadio

Enrico Bonadio

City University London - The City Law School

Date Written: 2012

Abstract

On 9th March 2012 the Indian Controller of Patents granted the first compulsory licence in India. Indian generics producer Natco Pharma Ltd. has been granted the right to produce and sell in India Bayer’s patented medicine “Sorafenib”, which is useful for treating advanced stage liver and kidney cancer. After a brief introduction on compulsory licenses under the TRIPS Agreement and the Paris Convention, the author verifies whether the decision of the Controller of Patents satisfies the conditions set forth by the these international treaties in relation to compulsory licenses. He concludes inter alia that the ruling might be in violation of the non discrimination principle enshrined in Article 27(1) TRIPS. General comments are also made about the role of compulsory licensing in guaranteeing the availability of patented products to a wide range of consumers and in general the transfer and dissemination of the associated technology.

Suggested Citation

Bonadio, Enrico, Compulsory Licensing of Patents: The Bayer/Natco Case (2012). (2012) European Intellectual Property Review (Issue 10), pp. 719-728, Available at SSRN: https://ssrn.com/abstract=2157477

Enrico Bonadio (Contact Author)

City University London - The City Law School ( email )

London, EC1V OHB
United Kingdom

HOME PAGE: http://www.city.ac.uk/law/

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
1,915
Abstract Views
6,136
Rank
15,962
PlumX Metrics